On August 26, 2026, the U.S. Food and Drug Administration granted approval to Rasonque (daraxonrasib), a drug created by Revolution Medicines, for patients with advanced pancreatic cancer who have already received prior treatment.
The approval is based on a late‑stage clinical trial that enrolled 500 participants at two Chicago hospitals. The study examined the drug’s safety and its effect on overall survival and disease progression, and the results satisfied the agency’s criteria for market authorization.
Trial data showed that Rasonque produced measurable improvements in survival metrics compared with existing options, while its safety profile aligned with expectations for this class of therapy. The investigators reported that adverse events were manageable and consistent with prior studies of similar agents.
Rasonque is positioned as an additional therapeutic line for individuals whose cancer has advanced despite earlier treatments. By offering a new mechanism of action, the drug is expected to be incorporated into treatment protocols as physicians assess suitability for each patient.
Revolution Medicines noted that the clearance expands its oncology portfolio, and the Chicago hospitals involved highlighted the trial’s role in delivering cutting‑edge care to local patients. Health providers anticipate prescribing the medication once insurance coverage and individual clinical judgments are in place.
The FDA may require post‑marketing surveillance to continue evaluating long‑term outcomes and safety in a broader patient population. Such monitoring is standard for newly approved oncology products.
The decision adds a new option to the limited arsenal against pancreatic cancer, a disease known for its high mortality and historically few effective treatments.